Restoring ITGA5 cleared damaged mitochondria and sped diabetic wound healing — in diabetic mice, human wound tissue and lab-grown endothelial cells

Edited by Samael A. Tejada, Founder & Editor-in-Chief

A diabetic wound that will not heal is often a blood-vessel problem before it is a skin problem. This study traces the failure into the vessel cells' mitochondria — iron-loaded, leaking oxidants, and not being cleared — and names the missing protein that normally keeps the cleanup running.

What is mitocytosis, and why does it matter here?

Cells have several ways to deal with damaged mitochondria. Mitophagy digests them internally. Mitocytosis is the export route: damaged mitochondria are loaded into migrasomes — small vesicles that bud from migrating cells — and expelled. In this study, ITGA5 promoted KIF5B-dependent mitocytosis in endothelial cells: KIF5B is the motor protein that hauls the cargo. When the team knocked KIF5B down, ITGA5's protection largely disappeared — evidence the disposal route, not just the protein's presence, does the work.

How does iron fit into a wound that won't heal?

High glucose pushed endothelial cells toward mitochondrial iron overload: more iron imported and stored (via transferrin receptor TfR1 and ferritin), less exported (via ferroportin, FPN1), feeding lipid peroxidation — the chemistry behind ferroptotic damage. ITGA5 restoration, acting through PI3K/AKT, rebalanced those iron-handling proteins, reduced mitochondrial iron accumulation and lipid peroxidation, and lowered mitochondrial reactive oxygen species. Blocking PI3K/AKT partially reversed the benefit, tying the effect to that signaling pathway.

What are the limits?

The human evidence is a tissue comparison — ITGA5 is lower in ulcers — which cannot by itself prove that raising ITGA5 would heal human wounds. The healing experiments used lentiviral overexpression in db/db mice, a delivery method nowhere near a clinic, and cultured endothelial cells. Diabetic wound care in people remains the unglamorous established work: pressure offloading, blood-flow assessment, infection control and glucose management. ITGA5 is a mechanism and a candidate direction, not a therapy.

Where the evidence stands

• Established: That mitochondrial dysfunction, oxidative stress and impaired angiogenesis contribute to diabetic wound chronicity is well supported; mitocytosis via migrasomes is a documented mitochondrial quality-control route.
• Preliminary: ITGA5's specific role: one study spanning human tissue observation, a diabetic mouse model and cell experiments, with a coherent mechanism (PI3K/AKT, iron handling, KIF5B-dependent mitocytosis) — awaiting independent replication.
• Absent: Any human treatment. No ITGA5-based therapy was given to patients.